| Antimicrobial Agent Abbreviations | |||||||||||||||
| Amp- Ampicilin, Amox/Clav- Amoxicillin/Clavulanate, Amp/Sulb-Ampicillin/Sulbactam, Amik- Amikacin, Aztre-Aztreonam, Cefaz- Cefazolin, Ceftaz-Ceftazidime, Cefep-Cefepime, Chloro-Chloramphenicol, Clinda-Clindamycin, Eryth-Erythromycin, Gent-Gentamicin, Imip-Imipenem, Levo-Levofloxacin,Linz-Linezolid, Mero-Meropenem, Nitro-Nitrofurantoin, Norflox- Norfloxacin, Naf-Nafcillin, Pen-Penicillin, Pip/Tazo-Pipercillin/Tazobactam, Tetra-Tetracycline, Tmp/Sxt- Trimethoprim/Sulfamethoxazole, Tobra-Tobramycin, Vanco-Vancomycin | |||||||||||||||
| HUP Inpatients, Jan-Dec 2007, Blood Isolates | |||||||||||||||
| Percent Susceptible | |||||||||||||||
| Organism | No | Amp or Pen | Amp/Sulb | Cefaz | Clinda | Eryth | Gent | Naf | Tmp/Sxt | Levo | Tetra | Linz | Vanco | ||
| S. aureus | 206 | 4 | 43 | 43 | 50 | 33 | 96 | 43 | 98 | 51 | 97 | 100 | 100 | ||
| Staphylococcus, coag neg | 200 | 4 | nt | 23 | 25** | 25 | 58 | 23 | nt | 24 | nt | 100 | 100 | ||
| Streptococcus, viridans group | 33 | 67 | nt | nt | nt | nt | nt | nt | nt | nt | nt | nt | 100 | ||
| Enterococcus sp | 223 | 40 | nt | nt | nt | 13 | 78(67)* | nt | nt | 22 | nt | 96 | 40 | ||
| *hl- high level gentamicin, 500 ug/ml, high level streptomycin, 2000 ug/ml, in parenthesis | |||||||||||||||
| **CNS not routinely tested for inducible clinidamycin resistance, susceptibily may be higher | |||||||||||||||
| Percent Susceptible | |||||||||||||||
| Organism | No. | Amp | Amp/Sulb or Amox/Clav | Aztre | Cefaz | Ceftaz | Cefep | Gent | Tobra | Amik | Levo | Pip (Pip/Tazo) | Tmp/Sxt | Mero | |
| A. baumannii | 15 | nt | 96 | nt | 0 | 40 | 47 | 60 | 60 | 73 | 33 | nt | 53 | 27 | |
| E. coli | 140 | 41 | nt | 88 | 84 | 89 | 90 | 87 | 86 | 99 | 63 | 58(87) | 68 | 99 | |
| E. cloacae | 37 | 0 | 0 | 46 | 0 | 58 | 76 | 76 | 62 | 97 | 76 | 44 | 62 | 100 | |
| K. pneumoniae | 113 | 0 | 67 | 79 | 74 | 75 | 75 | 80 | 76 | 80 | 77 | 2(72) | 70 | 84 | |
| K. oxytoca | 15 | 0 | 87 | 100 | 87 | 100 | 100 | 100 | 100 | 100 | 100 | 0(100) | 80 | 100 | |
| P. aeruginosa | 69 | nt | nt | nt | nt | 77 | 79 | 71 | 88 | 87 | 61 | 77 | nt | 76 | |
| S. marcescens | 24 | 0 | 0 | 100 | 0 | 100 | 100 | 100 | 96 | 100 | 100 | 96(100) | 100 | 100 | |
| HUP Inpatients, Jan-Dec 2007, Non-Urinary Isolates | |||||||||||||||
| Percent Susceptible | |||||||||||||||
| Organism | No | Amp or Pen | Amp/Sulb or Amox/Clav | Cefaz | Clinda | Ery | Gent | Naf | Tmp/Sxt | Levo | Tetra | Linz | Vanco | ||
| S. aureus | 722 | 4 | 42 | 42 | 59 | 32 | 97 | 42 | 96 | 57 | 96 | 100 | 100 | ||
| Staphylococcus, coag neg | 60 | 13 | 40 | 40 | 45 | 45 | 72 | 40 | nt | 57 | nt | 100 | 100 | ||
| Streptococcus intermedius/constellatus | 33 | 100 | nt | nt | nt | nt | nt | nt | nt | nt | nt | nt | 100 | ||
| Enterococcus sp | 281 | 61 | nt | nt | nt | 16 | nt | nt | nt | 39 | 45 | 90 | 62 | ||
| *CNS not tested for inducible clindamycin resistance, susceptibility may be higher | |||||||||||||||
| Organism | No. | Amp | Amp/Sulb or Amox/Clav | Aztr | Cefaz | Ceftaz | Cefep | Gent | Tobra | Amik | Levo | Mero | Pip (Pip/Tazo) | Tmp/Sxt | |
| A. baumannii | 53 | 0 | 80 | 2 | 0 | 31 | 29 | 57 | 69 | 78 | 31 | 30 | nt | 53 | |
| C. freundii | 14 | 0 | 0 | 78 | 0 | 79 | 88 | 53 | 67 | 100 | 73 | 100 | 50(nt) | 57 | |
| C. koseri | 22 | 0 | 0 | 94 | 95 | 100 | 100 | 96 | 96 | 100 | 100 | 100 | 0(nt) | 96 | |
| Pantoea (Enterobacter) aerogenes | 38 | 0 | 0 | 78 | 0 | 78 | 85 | 97 | 97 | 100 | 100 | 100 | 78(87) | 100 | |
| E. cloacae | 91 | 0 | 0 | 68 | 0 | 65 | 81 | 84 | 83 | 99 | 86 | 99 | 60(69) | 75 | |
| E. coli | 243 | 42 | nt | 94 | 78 | 96 | 96 | 86 | 83 | 98 | 65 | 100 | 60(92) | 70 | |
| K. pneumoniae | 160 | 0 | 61 | 68 | 67 | 72 | 71 | 81 | 71 | 74 | 71 | 77 | 0(66) | 66 | |
| K. oxytoca | 28 | 0 | 86 | 88 | 77 | 93 | 93 | 93 | 93 | 100 | 93 | 97 | 3(89) | 86 | |
| M. morganii | 24 | 0 | 0 | 93 | 0 | 79 | 100 | 83 | 100 | 100 | 92 | 100 | 79(96) | 83 | |
| P. mirabilis | 62 | 94 | 97 | 98 | 95 | 98 | 98 | 98 | 98 | 100 | 87 | 100 | 97(98) | 88 | |
| P. aeruginosa | 341 | nt | nt | nt | nt | 71 | 73 | 69 | 85 | 77 | 57 | 74 | 73 | nt | |
| S, marcescens | 44 | 0 | 0 | 200 | 0 | 100 | 100 | 100 | 100 | 100 | 80 | 100 | 100(100) | 96 | |
| HUP Inpatients, Jan-Dec 2007, Urinary Isolates | |||||||||||||||
| Percent Susceptible | |||||||||||||||
| Organism | No | Amp or Pen | Amp/Sulb or Amox/Clav | Cefaz | Ery | Clinda | Gent | Naf | Tmp/Sxt | Levo | Tetra | Linz | Vanco | ||
| S. aureus | 40 | 5 | 40 | 40 | 24 | 37 | 95 | 40 | 98 | 33 | 93 | 100 | 100 | ||
| Staphylococcus, coag neg | 179 | 6 | 29 | 29 | 23 | 23 | 68 | 23 | nt | 33 | nt | 100 | 100 | ||
| Enterococcus sp | 646 | 61 | nt | nt | 12 | nt | nt | nt | nt | 40 | 37 | 97 | 62 | ||
| *hl- high level gentamicin, 500 ug/ml, high level streptomycin, 2000 ug/ml, in parenthesis | |||||||||||||||
| **CNS not routinely tested for inducible clindamycin resistance, susceptibility may be higher | |||||||||||||||
| Percent Susceptible | |||||||||||||||
| Organism | No. | Amp | Amp/Sulb or Amox/Clav | Cefaz | Ceftaz | Gent | Tobra | Amik | Levo | Norflox | Nitro | Pip (Pip/Tazo) | Tmp/Sxt | Tetra | Mero |
| A. baumanii | 14 | 0 | 0 | 0 | 21 | 64 | 86 | 60 | 29 | 28 | 0 | nt | 43 | nt | 56 |
| C. koseri | 26 | 0 | 96 | 96 | 96 | 100 | 100 | nt | 100 | 100 | 85 | nt | 100 | 100 | nt |
| C. freundii | 28 | 0 | 0 | 0 | 82 | 93 | 93 | nt | 75 | 76 | 86 | nt | 79 | 72 | nt |
| Pantoea (Enterobacter) aerogenes | 30 | 0 | 0 | 0 | 80 | 97 | 97 | nt | 97 | 97 | 17 | nt | 97 | 97 | nt |
| E. cloacae | 61 | 0 | 0 | 0 | 72 | 74 | 73 | nt | 75 | 74 | 16 | nt | 61 | 75 | nt |
| E. coli | 938 | 50 | 78 | 87 | 97 | 90 | 92 | nt | 74 | 74 | 95 | nt | 73 | 75 | nt |
| K. pneumoniae | 324 | 0 | 78 | 73 | 77 | 84 | 75 | nt | 74 | 74 | 19 | nt | 70 | 75 | nt |
| K. oxytoca | 21 | 0 | 91 | 68 | 95 | 76 | 95 | nt | 86 | 86 | 95 | nt | 81 | 86 | nt |
| M. morganii | 16 | 0 | 0 | 0 | 100 | 88 | 88 | nt | 75 | 75 | 0 | nt | 69 | 75 | nt |
| P. mirabilis | 104 | 92 | 97 | 96 | 100 | 94 | 96 | nt | 82 | 84 | 0 | nt | 90 | 0 | nt |
| P. aeruginosa | 178 | nt | nt | nt | 84 | 72 | 85 | 86 | 59 | nt | nt | 82 | nt | nt | 79 |
| S. marcescens | 13 | 0 | 0 | 0 | 100 | 100 | 100 | nt | 100 | 100 | 0 | nt | 100 | 39 | nt |